Using a Unique Metabolic Approach to Treat Stage IV Metastatic Cancer.

Tyme Inc. is a clinical-stage biotechnology company developing novel cancer therapeutics, intended to be safe and effective across a broad range of tumor types. We are led by an experienced management team and advised by a distinguished board of directors. Tyme continues to build strong institutional collaborations that include Mt. Sinai, the Mayo Clinic and many others.

Our therapeutic intervention (SM-88) is designed to compromise cancer’s cellular defenses, exploiting its innate metabolic weaknesses, leading to cell death through oxidative stress and exposing cancer to the body’s natural immune system. SM-88’s profile is supported by over 5 years of clinical data in more than 100 metastatic subjects. Importantly, there have been no drug-related serious adverse effects.

Our lead clinical program, SM-88, an oral tyrosine-based therapy, is a first-in-class combination monotherapy that is currently in Phase II development for prostate cancer. Tyme is also preparing to initiate a Phase II clinical trial for pancreatic cancer in early 2018, and potentially other metastatic cancers later in 2018.

Tyme Inc. has multiple formulations for SM-88 including injectable, intranasal, and transdermal that are expected to be advanced into the clinical setting over time.

Tyme Inc. maintains a broad intellectual property portfolio of issues and pending patents covering our technologies and products well into the 2030’s